Back to Search
MARTIN RUBENSTEIN, MD
MD
Medical Oncology Physician
NPI: 1518928811Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
G34432(CA)
Hematology (Internal Medicine) Physician
Internal Medicine — Hematology
Code: 207RH0000X
G34432(CA)
Research & Publications (20)
Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2.
PMID 19533419·Med Oncol·2010
8-other
Regenerative patterning in Swarm Robots: mutual benefits of research in robotics and stem cell biology.
PMID 19557691·Int J Dev Biol·2009
7-preclinical
Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.
PMID 18686047·Med Oncol·2009
4-observational
Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2.
PMID 17972023·Med Oncol·2008
8-other
Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
PMID 17917084·Med Oncol·2007
8-other
Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
PMID 17848743·Med Oncol·2007
4-observational
Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy.
PMID 17136230·Methods Find Exp Clin Pharmacol·2006
8-other
Synthesis of branched antisense oligonucleotides having multiple specificities. Treatment of hormone insensitive prostate cancer.
PMID 16870352·Med Hypotheses·2006
8-other
Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors.
PMID 16023790·Med Hypotheses·2005
8-other
Short-term intravenous eptifibatide infusion combined with reduced dose recombinant tissue plasminogen activator inhibits platelet recruitment at sites of coronary artery injury.
PMID 14736451·J Am Coll Cardiol·2004
7-preclinical
Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and taxol.
PMID 12665682·Med Oncol·2003
4-observational
Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-alpha or EGFR in the treatment of prostate cancer cell lines.
PMID 12616956·Methods Find Exp Clin Pharmacol·2002
8-other
Biotinylation of antisense oligonucleotides does not alter lipofectin enhanced cellular uptake in prostate cancer cell lines.
PMID 11876021·Methods Find Exp Clin Pharmacol·2001
8-other
Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth factor-alpha and the epidermal growth factor receptor.
PMID 11778757·Med Oncol·2001
8-other
Effectiveness of and adverse events after percutaneous coronary intervention in patients with mild versus severe renal failure.
PMID 11274940·Am J Cardiol·2001
8-other
Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era?
PMID 11113047·Circulation·2000
3-trial
Do intra-tumor alkaline micro-regions represent additional therapeutically privileged sites?
PMID 18364249·Med Hypotheses·2008
7-preclinical
Local and systemic interleukin-18 and interleukin-18-binding protein in children with inflammatory bowel disease.
PMID 17879274·Inflamm Bowel Dis·2008
8-other
Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles.
PMID 17541843·J Drug Target·2007
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 50 E HAMILTON AVE, STE 200
CAMPBELL, CA 95008 - Phone
- (408) 376-2300
Quick Facts
- NPI
- 1518928811
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile